| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Since antibody-drug conjugates (ADCs) contain highly cytotoxic small molecules, the regulation of pharmacokinetics (including adequate release of cytotoxic molecules) is important to ensure efficacy and safety of ADCs. ADCs might have different binding properties to FcRn, Fc gamma R, and antigen from those of parental antibodies, and their pharmacokinetics might be different by binding state of compounds. However, the influences of the conjugation of compounds on pharmacokinetics have not been fully elucidated. Therefore, we produced various ADC models, elucidated the influences of the conjugation of compounds on the binding properties to antigens and Fc receptors, and established an imaging method that can analyze the release of compounds.
|
